BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 26910051)

  • 1. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
    Daver N; Cortes J; Kantarjian H; Ravandi F
    Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted therapy in acute myeloid leukemia.
    Gill H; Leung AY; Kwong YL
    Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
    Yilmaz M; Daver N
    Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.
    Foran JM
    Hematology; 2012 Apr; 17 Suppl 1():S137-40. PubMed ID: 22507802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial.
    Gorcea CM; Burthem J; Tholouli E
    Future Oncol; 2018 Aug; 14(20):1995-2004. PubMed ID: 29498296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
    Hauge M; Bruserud Ø; Hatfield KJ
    Eur J Haematol; 2016 Mar; 96(3):211-21. PubMed ID: 26465810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FLT3 inhibitors for acute myeloid leukemia.
    Lancet JE
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
    Fathi AT; Chen YB
    Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress in molecularly targeted therapies for acute myeloid leukemia].
    Tomita A
    Rinsho Ketsueki; 2015 Feb; 56(2):130-8. PubMed ID: 25765792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
    Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rocky road to personalized medicine in acute myeloid leukaemia.
    Brinda B; Khan I; Parkin B; Konig H
    J Cell Mol Med; 2018 Mar; 22(3):1411-1427. PubMed ID: 29327808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
    Lee CJ; Shiraz P; Muffly L
    Leuk Lymphoma; 2017 Mar; 58(3):516-527. PubMed ID: 27685315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted therapies for acute myeloid leukemia.
    Stein EM
    Hematology Am Soc Hematol Educ Program; 2015; 2015():579-83. PubMed ID: 26637775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The most novel of the novel agents for acute myeloid leukemia.
    Perl AE
    Curr Opin Hematol; 2018 Mar; 25(2):81-89. PubMed ID: 29278535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Therapeutics in Acute Myeloid Leukemia.
    DiNardo CD; Stone RM; Medeiros BC
    Am Soc Clin Oncol Educ Book; 2017; 37():495-503. PubMed ID: 28561688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.
    Miyamoto K; Minami Y
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Treatment Options for Acute Myeloid Leukemia in 2019.
    Cerrano M; Itzykson R
    Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.